On September 10, 2026, IceCure Medical Ltd. announced it received approval from China’s National Medical Products Administration (NMPA) to market its ProSense® system and associated cryoprobes as a Class III medical device in China. This regulatory milestone enables the commercialization of the company's flagship cryoablation technology in the Chinese market, expanding its global reach beyond existing approvals in the U.S., Europe, and Asia. IceCure Medical Ltd. develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors by freezing.

On August 24, 2026, IceCure Medical Ltd. announced an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands. The initial term is subject to negotiation of a longer-term agreement. This partnership supports market development and clinical education in a key European market where the independent THERMAC breast cancer trial has advanced to Phase III, highlighting cryoablation's high complete ablation rate. IceCure Medical Ltd. develops minimally-invasive liquid-nitrogen-based cryoablation therapy systems for tumor destruction.

On August 11, 2026, the Board of Directors approved an increase in ordinary shares reserved for issuance under the Company’s 2024 Employee Equity Incentive Plan by 2,500,000 shares. The total number of shares reserved increased from 112,667 to 2,612,667. This filing is incorporated by reference into existing Form F-3 and Form S-8 registration statements. IceCure Medical Ltd. operates in the medical device industry, developing cryoablation technology for cancer treatment.

IceCure Medical Ltd. reported first-half 2026 financial results showing a 45% year-over-year revenue increase to $1,818 thousand, driven by growth in system and disposable probe sales. Gross profit rose to $548 thousand from $349 thousand in the prior period. The company incurred a net loss of $8,775 thousand, with operating expenses increasing due to payroll, clinical trials for the CHoICE study, and foreign exchange impacts on NIS-denominated costs. Cash and cash equivalents stood at $12,034 thousand as of June 30, 2026, bolstered by approximately $8.5 million in gross proceeds from equity financings completed during the quarter, including a March registered direct offering and a June private placement. The filing also discloses that on June 4, 2026, the company effected a 1-for-30 reverse stock split. IceCure Medical Ltd. is a medical device company specializing in minimally invasive cryoablation technology for tumor destruction.

On August 11, 2026, IceCure Medical Ltd. announced that Vincent Chun Hung Chan resigned from its Board of Directors, effective August 14, 2026, with no disagreements cited. The Board appointed David Salton as an independent Class II director until the 2027 annual general meeting, assigning him to the Compensation, Audit, and Financial Statement Examination Committees. Salton currently serves as CEO of AnchorMesh Ltd. and holds prior board roles at SHL Telemedicine, ARAN Research & Development, and InterCure Inc. IceCure Medical Ltd. operates in the medical device industry, specializing in cryoablation therapies for cancer treatment.